Use: Labeled indications
- EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. (1)
Contraindications
4 CONTRAINDICATIONS EPSOLAY is contraindicated in patients with a history of hypersensitivity reactions to benzoyl peroxide or any components of the formulation in EPSOLAY [see Warnings and Precautions (5.1)]. A history of a serious hypersensitivity reactions to benzoyl peroxide or any component of the formulation in EPSOLAY. (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION Before initial use, prime the pump until the first drop of cream is released. Apply a pea-sized amount of EPSOLAY once daily in a thin layer to each area of the face (forehead, chin, nose, each cheek) on clean and dry skin. Avoid the eyes, lips and mouth. Wash hands after application. EPSOLAY may bleach hair or colored fabric.
EPSOLAY is for topical use only. Not for oral, ophthalmic, or intravaginal use. Discard unused EPSOLAY 60 days after first use. Apply to the affected areas once daily. (2) Wash hands after application. (2) Not for oral, ophthalmic, or intravaginal use. (2)
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of EPSOLAY for the treatment of inflammatory lesions of rosacea have not been established in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 733 subjects in the clinical trials of EPSOLAY, 127 (17%) subjects were 65 and over, while 37 (3%) subjects were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.
Dosage forms
Philippines
- Topical gel: 50 mg/g
- Gel: 50 mg/g
- W/w) gel: 50 mg/g (5 %
Registered products in the Philippines
7 products registered with the Food and Drug Administration (FDA) Philippines list Benzoyl peroxide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products7
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Acne Drying GelBenzoyl Peroxide | 50 mg/g (5%w/w) GelAluminum Tube x 5 g and 20 g (Box of 1's) | Rx | Zee LaboratoriesIndia | Intelligent Beauty Skin Solutions, Inc.Importer: Eon Pharmatek, Inc. | DR-XY47316 | Jun 29, 2031 | |
Benzac Spots TreatmentBenzoyl Peroxide | 10% GelLDPE Plastic Tube x 60 g (Box of 1 's) | OTC | Laboratoires GaldermaFrance | Importer: Galderma Philippines, Inc. | DR-XY1735 | Dec 9, 2031 | |
Benzac Spots TreatmentBenzoyl Peroxide | 10% Gel | OTC | Laboratoires Galderma | Importer: GALDERMA PHILIPPINES, INC. | DR-XY17355 | Dec 9, 2026 | |
Benzac Spots TreatmentBenzoyl Peroxide | 50 mg/g (5% w/w) Gel | OTC | Laboratoires Galderma | Importer: Galderma Philippines, Inc. | DR-XY16211 | Dec 9, 2026 | |
BenzomedBenzoyl Peroxide | 50mg/g (5% w/w) Topical GelAluminum Collapsible Tube x 15g (Box of l's) | OTC | Blossom PharmaceuticalsIndia | Medinova Pharmaceutical Inc. | DRP-11205 | Feb 11, 2027 | |
BenzoperBenzoyl Peroxide | 50 mg/g (5% w/w) Topical GelAluminum Collapsible Tube x 5 g (Box of 1's); Aluminum Collapsible Tube x 20 g (Box of 1's) | Rx | Zee LaboratoriesIndia | Eon Pharmatek, Inc.Importer: Eon Pharmatek, Inc | DR-XY42508 | Sep 2, 2028 | |
BenzoperBenzoyl Peroxide | 50 mg/g (5% w/w) Topical GelAluminum Collapsible Tube x 5 g (Box of 1's); Aluminum Collapsible Tube x 20 g (Box of 1's) | Rx | Zee LaboratoriesIndia | Eon Pharmatek Inc. | DRP-15047 | Sep 2, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Cream, 5%. Each gram of EPSOLAY contains 50 mg of benzoyl peroxide in a white to off-white base. Cream, 5%. (3)
Warnings/Precautions
- Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with the use of benzoyl peroxide products. (5.1)
- Skin irritation/contact dermatitis: Erythema, scaling, dryness, stinging/burning, irritation and allergic contact dermatitis may occur with use of EPSOLAY and may necessitate discontinuation. (5.2)
- Photosensitivity: Avoid or minimize exposure to natural or artificial sunlight and use sun protection measures. (5.3)
5.1 Hypersensitivity
5.1 Hypersensitivity Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported with the use of benzoyl peroxide products. If a serious hypersensitivity reaction occurs, discontinue EPSOLAY immediately and initiate appropriate therapy.
5.2 Skin Irritation/Contact Dermatitis
5.2 Skin Irritation/Contact Dermatitis Erythema, scaling, dryness and stinging/burning may be experienced with use of EPSOLAY. Irritation and contact dermatitis may occur. Apply a moisturizer and discontinue EPSOLAY if symptoms do not improve. Avoid application of EPSOLAY to cuts, abrasions, eczematous or sunburned skin.
5.3 Photosensitivity
5.3 Photosensitivity Benzoyl peroxide may increase sensitivity to sunlight. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using EPSOLAY. Instruct the patient to implement sun protection measures (e.g., sunscreen and loose- fitting clothes) when sun exposure cannot be avoided.
Discontinue EPSOLAY at the first evidence of sunburn.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS Most common adverse reactions (incidence ≥ 1%) are application site reactions: pain, erythema, pruritis and edema. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two randomized, double-blind, vehicle-controlled trials, adult subjects with rosacea applied EPSOLAY (N = 488) or vehicle (N = 234) once daily for 12 weeks. The majority of subjects were Caucasian (93%) and female (73%) with a mean age of 51 years. Table 1 presents the most common adverse reactions occurring in ≥ 1% of subjects treated with EPSOLAY and more frequently than in subjects treated with vehicle.
Table 1: Adverse Reactions Occurring in ≥ 1% of Subjects Treated with EPSOLAY and with Greater Frequency than Subjects Treated with Vehicle EPSOLAY N=488 Vehicle N=234 Application site pain 11 (2%) 2 (1%) Application site erythema 11 (2%) 2 (1%) Application site pruritus 6 (1%) 1 (<1%) Application site edema Application site edema includes: application site swelling and application site edema 4 (1%) 0 (0%) During the clinical trials, local tolerability evaluations were conducted at baseline and at each study visit by assessment of dryness, itching, scaling and stinging/burning. Table 2 presents the local tolerability assessments by severity grade at Week 12.
Table 2: Facial Cutaneous Tolerability Assessment Sign/Symptom EPSOLAY N=455 Of the 488 subjects treated with EPSOLAY, 455 subjects had local tolerability assessments at Week 12. Severity at Week 12 Mild Moderate Severe Dryness 25% 7% 0% Itching 24% 6% 0% Scaling 13% 4% 0% Stinging/Burning 20% 3% 1% In a 40-week open-label extension safety study (for a total of up to 52 weeks of treatment) the frequency and severity of local tolerability signs and symptoms at Week 52 were comparable to those reported at Week 12.
Adverse reaction frequency tables (US label) US FDA label
| EPSOLAY N=488 | Vehicle N=234 | |
|---|---|---|
| Application site pain | 11 (2%) | 2 (1%) |
| Application site erythema | 11 (2%) | 2 (1%) |
| Application site pruritus | 6 (1%) | 1 (<1%) |
| Application site edemaApplication site edema includes: application site swelling and application site edema | 4 (1%) | 0 (0%) |
| Sign/Symptom | EPSOLAY N=455Of the 488 subjects treated with EPSOLAY, 455 subjects had local tolerability assessments at Week 12. | ||
|---|---|---|---|
| Severity at Week 12 | |||
| Mild | Moderate | Severe | |
| Dryness | 25% | 7% | 0% |
| Itching | 24% | 6% | 0% |
| Scaling | 13% | 4% | 0% |
| Stinging/Burning | 20% | 3% | 1% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary The systemic exposure of benzoyl peroxide is unknown. Based on the published literature, benzoyl peroxide is metabolized to benzoic acid (an endogenous substance), which is eliminated in the urine. Hence, maternal use is not expected to result in fetal exposure to the drug. Animal reproductive studies have not been conducted with EPSOLAY or benzoyl peroxide.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Mechanism of action
12.1 Mechanism of Action Benzoyl peroxide is an oxidizing agent with bactericidal and keratolytic effects but the precise mechanism of action in the treatment of rosacea is unknown.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The pharmacodynamics of EPSOLAY in the treatment of rosacea are unknown.
Pharmacokinetics
12.3 Pharmacokinetics Benzoyl peroxide is absorbed by the skin where it is converted to benzoic acid, an endogenous substance, which is eliminated in the urine.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Benzoyl peroxide is absorbed by the skin where it is converted to benzoic acid, an endogenous substance, which is eliminated in the urine. The systemic exposure of benzoyl peroxide following the application of EPSOLAY was not assessed.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Benzoyl Peroxide |
| PNF listing | Gel: 5%, 20 g tube |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Epsolay · Mayne Pharma Commercial LLC [US FDA-approved label, version 2, August 11, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=641981e6-460b-44dd-8146-306c47e5367c
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .